ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy

Beyoglu, Diren; Idle, Jeffrey R.*
Metabolites2020-2DOI: 10.3390/metabo10020050
56被引4阅读
引用收藏
分享

摘要

In recent years, there has been a plethora of attempts to discover biomarkers that are more reliable than alpha-fetoprotein for the early prediction and prognosis of hepatocellular carcinoma (HCC). Efforts have involved such fields as genomics, transcriptomics, epigenetics, microRNA, exosomes, proteomics, glycoproteomics, and metabolomics. HCC arises against a background of inflammation, steatosis, and cirrhosis, due mainly to hepatic insults caused by alcohol abuse, hepatitis B and C virus infection, adiposity, and diabetes. Metabolomics offers an opportunity, without recourse to liver biopsy, to discover biomarkers for premalignant liver disease, thereby alerting the potential of impending HCC. We have reviewed metabolomic studies in alcoholic liver disease (ALD), cholestasis, fibrosis, cirrhosis, nonalcoholic fatty liver (NAFL), and nonalcoholic steatohepatitis (NASH). Specificity was our major criterion in proposing clinical evaluation of indole-3-lactic acid, phenyllactic acid, N-lauroylglycine, decatrienoate, N-acetyltaurine for ALD, urinary sulfated bile acids for cholestasis, cervonoyl ethanolamide for fibrosis, 16 alpha-hydroxyestrone for cirrhosis, and the pattern of acyl carnitines for NAFL and NASH. These examples derive from a large body of published metabolomic observations in various liver diseases in adults, adolescents, and children, together with animal models. Many other options have been tabulated. Metabolomic biomarkers for premalignant liver disease may help reduce the incidence of HCC.

学科与关键词

关键词
metabolomicslipidomicsbiomarkerpremalignantalcoholic liver diseasecholestasisfibrosiscirrhosisNAFLNASH
相关
加载中…
  • Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests
    Masoodi, Mojgan*; Gastaldelli, Amalia; Hyotylainen, Tuulia; Arretxe, Enara; Alonso, Cristina; Gaggini, Melania; Brosnan, Julia; Anstee, Quentin M.; Millet, Oscar; Ortiz, Pablo; Mato, Jose M.; Dufour, Jean-Francois; Oresic, Matej*Nature Reviews. Gastroenterology and Hepatology, 2021, 18(12): 835-856.被引 236
  • Microbiome and Metabolomics in Liver Cancer: Scientific Technology
    Ganesan, Raja; Yoon, Sang Jun; Suk, Ki Tae*INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24(1): 537.被引 15
  • A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry
    Yin, Peiyuan*; Wan, Dafang; Zhao, Chunxia; Chen, Jing; Zhao, Xinjie; Wang, Wenzhao; Lu, Xin; Yang, Shengli; Gu, Jianren; Xu, GuowangMolecular BioSystems, 2009, 5(8): 868-876.被引 195
查看全部 →

发表信息

论文状态
公开发表
期刊
Metabolites
发表日期
2020-02
卷期
第 10 卷, 第 2 期
页码
50
DOI
10.3390/metabo10020050
期刊收录
NSL.SCIE
期刊等级
4区
成果收录
SCIE
资助标注
Long Island University; offices of the Senior Vice President for Academic Affairs, Long Island University

作者

  • B

    Beyoglu, Diren (第一作者)

  • I

    Idle, Jeffrey R. (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417